Transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) affects far more patients than most health systems realize — and the data show many are going undiagnosed and unmanaged.1-7 Recent Becker’s Healthcare and Alnylam survey research, with perspectives from more than 100 health system leaders,…
Presented by:
Presenters
Ginger Biesbrock, DSc, PA-C, MPH, FACC
Nitasha Sarswat, MD
Joshua S. Weber, PharmD, MBA-HCM, CSP, DPLA, 340B ACE
